|
Nomograms for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Merck Serono; Roche/Genentech; Sanofi |
Consulting or Advisory Role - Merck Serono; Roche/Genentech; Sanofi |
Speakers' Bureau - Merck Serono; Roche/Genentech; Sanofi |
Travel, Accommodations, Expenses - Merck Serono; Roche/Genentech; Sanofi |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Abbott Biotherapeutics; Bayer; Boehringer Ingelheim; pfizer; Roche/Genentech; Sun Pharma |
Research Funding - Taiho Pharmaceutical |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Roche; Sanofi |
Speakers' Bureau - Roche; Sanofi |
| |
|
No Relationships to Disclose |